{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:51:04Z","timestamp":1790819464974,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00277-018-3562-8","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T01:27:42Z","timestamp":1542936462000},"page":"561-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-6539","authenticated-orcid":false,"given":"Ayman","family":"Qasrawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waled","family":"Bahaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Qasrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abughanimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Foxworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"issue":"12","key":"3562_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"3562_CR2","volume-title":"Cancer facts & figures 2017","author":"American Cancer Society","year":"2017","unstructured":"American Cancer Society (2017) Cancer facts & figures 2017. American Cancer Society, Atlanta"},{"issue":"17","key":"3562_CR3","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser O, Trama A, Maynadi\u00e9 M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257\u20133266. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.024","journal-title":"Eur J Cancer"},{"issue":"12","key":"3562_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.29319","volume":"121","author":"ME Percival","year":"2015","unstructured":"Percival ME, Tao L, Medeiros BC, Clarke CA (2015) Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer 121(12):2004\u20132012. https:\/\/doi.org\/10.1002\/cncr.29319","journal-title":"Cancer"},{"issue":"4","key":"3562_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"16","key":"3562_CR6","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1200\/JCO.2004.99.116","volume":"22","author":"U Creutzig","year":"2004","unstructured":"Creutzig U, Kaspers GJ (2004) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 22(16):3432\u20133433. https:\/\/doi.org\/10.1200\/JCO.2004.99.116","journal-title":"J Clin Oncol"},{"issue":"3","key":"3562_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.critrevonc.2007.09.008","volume":"66","author":"F Ferrara","year":"2008","unstructured":"Ferrara F, Palmieri S, Leoni F (2008) Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66(3):181\u2013193. https:\/\/doi.org\/10.1016\/j.critrevonc.2007.09.008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"3562_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249\u20131259. https:\/\/doi.org\/10.1056\/NEJMoa0904544","journal-title":"N Engl J Med"},{"issue":"5","key":"3562_CR9","doi-asserted-by":"publisher","first-page":"e0125612","DOI":"10.1371\/journal.pone.0125612","volume":"10","author":"Q Gong","year":"2015","unstructured":"Gong Q, Zhou L, Xu S, Li X, Zou Y, Chen J (2015) High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials. PLoS One 10(5):e0125612. https:\/\/doi.org\/10.1371\/journal.pone.0125612","journal-title":"PLoS One"},{"issue":"8","key":"3562_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.leukres.2013.04.009","volume":"37","author":"S Trifilio","year":"2013","unstructured":"Trifilio S, Zhou Z, Mehta J, Czerniak C, Pi J, Greenberg D, Koslosky M, Pantiru M, Altman J (2013) Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Leuk Res 37(8):868\u2013871. https:\/\/doi.org\/10.1016\/j.leukres.2013.04.009","journal-title":"Leuk Res"},{"issue":"1","key":"3562_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53\u201361. https:\/\/doi.org\/10.1182\/blood-2015-08-604520","journal-title":"Blood"},{"key":"3562_CR12","doi-asserted-by":"publisher","first-page":"CD010432","DOI":"10.1002\/14651858.CD010432.pub2","volume":"6","author":"X Li","year":"2015","unstructured":"Li X, Xu S, Tan Y, Chen J (2015) The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. Cochrane Database Syst Rev 6:CD010432. https:\/\/doi.org\/10.1002\/14651858.CD010432.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"3562_CR13","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE, Group UNAS (2015) A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25):3878\u20133885. https:\/\/doi.org\/10.1182\/blood-2015-01-623447","journal-title":"Blood"},{"issue":"3","key":"3562_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2016-04-712091","volume":"128","author":"AK Burnett","year":"2016","unstructured":"Burnett AK, Russell NH, Hills RK, Group UKNCRIAMLS (2016) Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 128(3):449\u2013452. https:\/\/doi.org\/10.1182\/blood-2016-04-712091","journal-title":"Blood"},{"issue":"8","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/sj.leu.2403009","volume":"17","author":"RF Schlenk","year":"2003","unstructured":"Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fr\u00f6hling S, D\u00f6hner K, Haas R, D\u00f6hner H, AML Study Group Ulm (AMLSG ULM) (2003) Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 17(8):1521\u20131528. https:\/\/doi.org\/10.1038\/sj.leu.2403009","journal-title":"Leukemia"},{"issue":"10","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"e110153","DOI":"10.1371\/journal.pone.0110153","volume":"9","author":"W Li","year":"2014","unstructured":"Li W, Gong X, Sun M, Zhao X, Gong B, Wei H, Mi Y, Wang J (2014) High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One 9(10):e110153. https:\/\/doi.org\/10.1371\/journal.pone.0110153","journal-title":"PLoS One"},{"issue":"3","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","volume":"32","author":"R Willemze","year":"2014","unstructured":"Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefr\u00e8re F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32(3):219\u2013228. https:\/\/doi.org\/10.1200\/JCO.2013.51.8571","journal-title":"J Clin Oncol"},{"key":"3562_CR18","doi-asserted-by":"publisher","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol:JCO2017776112. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112","DOI":"10.1200\/JCO.2017.77.6112"},{"issue":"2","key":"3562_CR19","first-page":"97","volume":"70","author":"S Miyawaki","year":"1999","unstructured":"Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R (1999) No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 70(2):97\u2013104","journal-title":"Japan Adult Leukemia Study Group Int J Hematol"},{"issue":"13","key":"3562_CR20","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","volume":"98","author":"EH Estey","year":"2001","unstructured":"Estey EH, Thall PF, Cortes JE, Giles FJ, O\u2019Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98(13):3575\u20133583","journal-title":"Blood"},{"issue":"7","key":"3562_CR21","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","volume":"89","author":"IM Hann","year":"1997","unstructured":"Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council\u2019s 10th AML trial (MRC AML10). Adult and childhood leukaemia working parties of the Medical Research Council. Blood 89(7):2311\u20132318","journal-title":"Blood"},{"issue":"5","key":"3562_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"3562_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11899-017-0381-2","volume":"12","author":"MB Leick","year":"2017","unstructured":"Leick MB, Levis MJ (2017) The future of targeting FLT3 activation in AML. Curr Hematol Malig Rep 12:153\u2013167. https:\/\/doi.org\/10.1007\/s11899-017-0381-2","journal-title":"Curr Hematol Malig Rep"},{"issue":"22","key":"3562_CR24","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum FR, Bernstein ID (2017) Gemtuzumab ozogamicin for acute myeloid leukemia. Blood 130(22):2373\u20132376. https:\/\/doi.org\/10.1182\/blood-2017-09-797712","journal-title":"Blood"},{"issue":"9825","key":"3562_CR25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H, Association ALF (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508\u20131516. https:\/\/doi.org\/10.1016\/S0140-6736(12)60485-1","journal-title":"Lancet"},{"key":"3562_CR26","doi-asserted-by":"publisher","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S (2018) Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica https:\/\/doi.org\/10.3324\/haematol.2018.188888 , haematol.2018.188888","DOI":"10.3324\/haematol.2018.188888"},{"issue":"48","key":"3562_CR27","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1038\/onc.2010.375","volume":"29","author":"KC Queiroz","year":"2010","unstructured":"Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA (2010) Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29(48):6314\u20136322. https:\/\/doi.org\/10.1038\/onc.2010.375","journal-title":"Oncogene"},{"issue":"2","key":"3562_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/ml2002423","volume":"3","author":"MJ Munchhof","year":"2012","unstructured":"Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT (2012) Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett 3(2):106\u2013111. https:\/\/doi.org\/10.1021\/ml2002423","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"3562_CR29","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","volume":"2","author":"G Martinelli","year":"2015","unstructured":"Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O\u2019Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C (2015) Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol 2(8):e339\u2013e346. https:\/\/doi.org\/10.1016\/S2352-3026(15)00096-4","journal-title":"Lancet Haematol"},{"issue":"10","key":"3562_CR30","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","volume":"24","author":"MR Savona","year":"2018","unstructured":"Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O\u2019Connell A, Chan G, Cortes JE (2018) Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res 24(10):2294\u20132303. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2824","journal-title":"Clin Cancer Res"},{"key":"3562_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V128.22.99.99","volume":"128","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, Fernandez PM, Ma WW, Shaik MN, Zeremski M, O\u2019Connell A, Chan G (2016) A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 128:99","journal-title":"Blood"},{"issue":"11","key":"3562_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O\u2019Connell A, Chan G, Schroeder MA (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93(11):1301\u20131310. https:\/\/doi.org\/10.1002\/ajh.25238","journal-title":"Am J Hematol"},{"key":"3562_CR33","volume-title":"Biochemistry","author":"RA Harvey","year":"2011","unstructured":"Harvey RA, Ferrier DR (2011) Biochemistry, 5th edn. Wolters Kluwer Health\/Lippincott Williams & Wilkins, Philadelphia","edition":"5"},{"key":"3562_CR34","volume-title":"Principles of medical biochemistry","author":"G Meisenberg","year":"2012","unstructured":"Meisenberg G, Simmons WH (2012) Principles of medical biochemistry, 3rd edn. Elsevier\/ Saunders, Philadelphia","edition":"3"},{"issue":"7","key":"3562_CR35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/1042819031000077142","volume":"44","author":"CM Galmarini","year":"2003","unstructured":"Galmarini CM, Jordheim L, Dumontet C (2003) Role of IMP-selective 5\u2032-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 44(7):1105\u20131111. https:\/\/doi.org\/10.1080\/1042819031000077142","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3562_CR36","doi-asserted-by":"publisher","first-page":"9431","DOI":"10.3390\/ijms16059431","volume":"16","author":"M Fasullo","year":"2015","unstructured":"Fasullo M, Endres L (2015) Nucleotide salvage deficiencies, DNA damage and neurodegeneration. Int J Mol Sci 16(5):9431\u20139449. https:\/\/doi.org\/10.3390\/ijms16059431","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3562_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nsb942","volume":"10","author":"E Sabini","year":"2003","unstructured":"Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10(7):513\u2013519. https:\/\/doi.org\/10.1038\/nsb942","journal-title":"Nat Struct Biol"},{"issue":"3","key":"3562_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jmb.2008.02.061","volume":"378","author":"E Sabini","year":"2008","unstructured":"Sabini E, Hazra S, Ort S, Konrad M, Lavie A (2008) Structural basis for substrate promiscuity of dCK. J Mol Biol 378(3):607\u2013621. https:\/\/doi.org\/10.1016\/j.jmb.2008.02.061","journal-title":"J Mol Biol"},{"issue":"7","key":"3562_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","volume":"26","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26(7):621\u2013629","journal-title":"Leuk Res"},{"issue":"2","key":"3562_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pharmthera.2003.07.001","volume":"100","author":"AR Rompay Van","year":"2003","unstructured":"Van Rompay AR, Johansson M, Karlsson A (2003) Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 100(2):119\u2013139","journal-title":"Pharmacol Ther"},{"key":"3562_CR41","doi-asserted-by":"publisher","unstructured":"Bianchi V, Spychala J (2003) Mammalian 5\u2032-nucleotidases. J Biol Chem 278(47):46195\u201346198. https:\/\/doi.org\/10.1074\/jbc.R300032200","DOI":"10.1074\/jbc.R300032200"},{"issue":"2","key":"3562_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1385\/MO:21:2:187","volume":"21","author":"D Vannoni","year":"2004","unstructured":"Vannoni D, Bernini A, Carlucci F, Civitelli S, Di Pietro MC, Leoncini R, Rosi F, Tabucchi A, Tanzini G, Marinello E (2004) Enzyme activities controlling adenosine levels in normal and neoplastic tissues. Med Oncol 21(2):187\u2013195. https:\/\/doi.org\/10.1385\/MO:21:2:187","journal-title":"Med Oncol"},{"issue":"3","key":"3562_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0022-3476(97)70199-9","volume":"130","author":"RH Buckley","year":"1997","unstructured":"Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM (1997) Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130(3):378\u2013387","journal-title":"J Pediatr"},{"key":"3562_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fimmu.2012.00265","volume":"3","author":"AV Sauer","year":"2012","unstructured":"Sauer AV, Brigida I, Carriglio N, Aiuti A (2012) Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol 3:265. https:\/\/doi.org\/10.3389\/fimmu.2012.00265","journal-title":"Front Immunol"},{"issue":"11","key":"3562_CR45","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","volume":"77","author":"DA Carson","year":"1980","unstructured":"Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW, Robins RK, Montgomery JA (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 77(11):6865\u20136869","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"3562_CR46","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"LD Piro","year":"1990","unstructured":"Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322(16):1117\u20131121. https:\/\/doi.org\/10.1056\/NEJM199004193221605","journal-title":"N Engl J Med"},{"issue":"3","key":"3562_CR47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","volume":"72","author":"LD Piro","year":"1988","unstructured":"Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72(3):1069\u20131073","journal-title":"Blood"},{"issue":"7","key":"3562_CR48","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","volume":"81","author":"DA Carson","year":"1984","unstructured":"Carson DA, Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine. Proc Natl Acad Sci U S A 81(7):2232\u20132236","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3562_CR49","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1200\/JCO.1991.9.3.416","volume":"9","author":"VM Santana","year":"1991","unstructured":"Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL (1991) A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9(3):416\u2013422. https:\/\/doi.org\/10.1200\/JCO.1991.9.3.416","journal-title":"J Clin Oncol"},{"key":"3562_CR50","doi-asserted-by":"publisher","unstructured":"Owen RP, Badagnani I, Giacomini KM (2006) Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem 281(36):26675\u201326682. https:\/\/doi.org\/10.1074\/jbc.M513421200","DOI":"10.1074\/jbc.M513421200"},{"issue":"3","key":"3562_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.leu.2403271","volume":"18","author":"M Pastor-Anglada","year":"2004","unstructured":"Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J (2004) Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18(3):385\u2013393. https:\/\/doi.org\/10.1038\/sj.leu.2403271","journal-title":"Leukemia"},{"issue":"10","key":"3562_CR52","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/1042819031000099698","volume":"44","author":"K Lotfi","year":"2003","unstructured":"Lotfi K, Juliusson G, Albertioni F (2003) Pharmacological basis for cladribine resistance. Leuk Lymphoma 44(10):1705\u20131712. https:\/\/doi.org\/10.1080\/1042819031000099698","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"3562_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/10428194.2011.570394","volume":"52","author":"JB Johnston","year":"2011","unstructured":"Johnston JB (2011) Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):43\u201345. https:\/\/doi.org\/10.3109\/10428194.2011.570394","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3562_CR54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","volume":"62","author":"DA Carson","year":"1983","unstructured":"Carson DA, Wasson DB, Taetle R, Yu A (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62(4):737\u2013743","journal-title":"Blood"},{"issue":"24 Pt 1","key":"3562_CR55","first-page":"6923","volume":"49","author":"J Griffig","year":"1989","unstructured":"Griffig J, Koob R, Blakley RL (1989) Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 49(24 Pt 1):6923\u20136928","journal-title":"Cancer Res"},{"issue":"1","key":"3562_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajh.23862","volume":"90","author":"CW Freyer","year":"2015","unstructured":"Freyer CW, Gupta N, Wetzler M, Wang ES (2015) Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol 90(1):62\u201372. https:\/\/doi.org\/10.1002\/ajh.23862","journal-title":"Am J Hematol"},{"key":"3562_CR57","doi-asserted-by":"crossref","unstructured":"Schellens J, McLeod H, Newell D (2005) Cancer clinical pharmacology. 1st edn. Oxford University Press,","DOI":"10.1093\/oso\/9780192629661.001.0001"},{"issue":"5","key":"3562_CR58","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0026-895X(25)10210-1","volume":"45","author":"P Hentosh","year":"1994","unstructured":"Hentosh P, Grippo P (1994) Template 2-chloro-2\u2032-deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol Pharmacol 45(5):955\u2013961","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3562_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/abbi.1993.1175","volume":"302","author":"SK Chunduru","year":"1993","unstructured":"Chunduru SK, Appleman JR, Blakley RL (1993) Activity of human DNA polymerases alpha and beta with 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 302(1):19\u201330. https:\/\/doi.org\/10.1006\/abbi.1993.1175","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"3562_CR60","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/sj.leu.2402114","volume":"15","author":"CM Galmarini","year":"2001","unstructured":"Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15(6):875\u2013890","journal-title":"Leukemia"},{"issue":"6","key":"3562_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.exphem.2015.02.001","volume":"43","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS (2015) Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: enhancement of cytotoxicity with epigenetic modulators. Exp Hematol 43(6):448\u2013461.e442. https:\/\/doi.org\/10.1016\/j.exphem.2015.02.001","journal-title":"Exp Hematol"},{"issue":"1","key":"3562_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0959-8049(96)00347-4","volume":"33","author":"K Warzocha","year":"1997","unstructured":"Warzocha K, Fabianowska-Majewska K, Blo\u0144ski J, Krykowski E, Robak T (1997) 2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia. Eur J Cancer 33(1):170\u2013173","journal-title":"Eur J Cancer"},{"issue":"2","key":"3562_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0006-2952(02)01486-7","volume":"65","author":"D Wyczechowska","year":"2003","unstructured":"Wyczechowska D, Fabianowska-Majewska K (2003) The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 65(2):219\u2013225","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"3562_CR64","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","volume":"96","author":"D Genini","year":"2000","unstructured":"Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM (2000) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96(10):3537\u20133543","journal-title":"Blood"},{"issue":"15","key":"3562_CR65","first-page":"4187","volume":"60","author":"AR Pettitt","year":"2000","unstructured":"Pettitt AR, Sherrington PD, Cawley JC (2000) Role of poly (ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 60(15):4187\u20134193","journal-title":"Cancer Res"},{"issue":"16","key":"3562_CR66","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","volume":"116","author":"DS Sigal","year":"2010","unstructured":"Sigal DS, Miller HJ, Schram ED, Saven A (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116(16):2884\u20132896. https:\/\/doi.org\/10.1182\/blood-2010-02-246140","journal-title":"Blood"},{"issue":"10","key":"3562_CR67","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V78.10.2583.2583","volume":"78","author":"AL Petzer","year":"1991","unstructured":"Petzer AL, Bilgeri R, Zilian U, Haun M, Geisen FH, Pragnell I, Braunsteiner H, Konwalinka G (1991) Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 78(10):2583\u20132587","journal-title":"Blood"},{"key":"3562_CR68","volume-title":"Acute leukemias: pharmacokinetics and management of relapsed and refractory disease","author":"W Plunkett","year":"1992","unstructured":"Plunkett W, Gandhi V, Kantarjian H, Keating M (1992) Pharmacologically guided leukemia therapy. In: Hiddemann W, B\u00fcchner T, W\u00f6rmann B et al (eds) Acute leukemias: pharmacokinetics and management of relapsed and refractory disease. Springer, Berlin"},{"issue":"23","key":"3562_CR69","doi-asserted-by":"publisher","first-page":"9043","DOI":"10.1021\/bi00449a012","volume":"28","author":"MY Kim","year":"1989","unstructured":"Kim MY, Ives DH (1989) Human deoxycytidine kinase: kinetic mechanism and end product regulation. Biochemistry 28(23):9043\u20139047","journal-title":"Biochemistry"},{"issue":"Suppl","key":"3562_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/10428199309149122","volume":"10","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10(Suppl):109\u2013114. https:\/\/doi.org\/10.3109\/10428199309149122","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3562_CR71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","volume":"87","author":"V Gandhi","year":"1996","unstructured":"Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87(1):256\u2013264","journal-title":"Blood"},{"issue":"10","key":"3562_CR72","first-page":"1563","volume":"10","author":"SM Kornblau","year":"1996","unstructured":"Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O\u2019Brien S, Plunkett W, Estey E (1996) Clinical and laboratory studies of 2-chlorodeoxyadenosine +\/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10(10):1563\u20131569","journal-title":"Leukemia"},{"issue":"2","key":"3562_CR73","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J (1997) The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 32(2):120\u2013131. https:\/\/doi.org\/10.2165\/00003088-199732020-00003","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3562_CR74","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.1996.14.3.978","volume":"14","author":"A Saven","year":"1996","unstructured":"Saven A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, Piro LD (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 14(3):978\u2013983. https:\/\/doi.org\/10.1200\/JCO.1996.14.3.978","journal-title":"J Clin Oncol"},{"issue":"10","key":"3562_CR75","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","volume":"10","author":"J Liliemark","year":"1992","unstructured":"Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2\u2032-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10(10):1514\u20131518. https:\/\/doi.org\/10.1200\/JCO.1992.10.10.1514","journal-title":"J Clin Oncol"},{"issue":"6","key":"3562_CR76","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/BF02440863","volume":"44","author":"F Albertioni","year":"1993","unstructured":"Albertioni F, Juliusson G, Liliemark J (1993) On the bioavailability of 2-chloro-2\u2032-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 44(6):579\u2013582","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3562_CR77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2004.03.007","volume":"210","author":"S Lindemalm","year":"2004","unstructured":"Lindemalm S, Liliemark J, Juliusson G, Larsson R, Albertioni F (2004) Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 210(2):171\u2013177. https:\/\/doi.org\/10.1016\/j.canlet.2004.03.007","journal-title":"Cancer Lett"},{"issue":"5","key":"3562_CR78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S\u00f8rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, Group CS (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362(5):416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"issue":"1","key":"3562_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428199109068099","volume":"5","author":"E Beutler","year":"1991","unstructured":"Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, Carrera CJ, Morin P, Carson DA (1991) 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 5(1):1\u20138. https:\/\/doi.org\/10.3109\/10428199109068099","journal-title":"Leuk Lymphoma"},{"issue":"8825","key":"3562_CR80","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"E Beutler","year":"1992","unstructured":"Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340(8825):952\u2013956","journal-title":"Lancet"},{"issue":"20","key":"3562_CR81","first-page":"5570","volume":"51","author":"J Liliemark","year":"1991","unstructured":"Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine in humans. Cancer Res 51(20):5570\u20135572","journal-title":"Cancer Res"},{"issue":"4","key":"3562_CR82","first-page":"385","volume":"1","author":"J Liliemark","year":"1995","unstructured":"Liliemark J, Juliusson G (1995) Cellular pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1(4):385\u2013390","journal-title":"Clin Cancer Res"},{"key":"3562_CR83","volume-title":"Cancer chemotherapy and biotherapy: principles and practice","author":"B Chabner","year":"2011","unstructured":"Chabner B, Longo D (2011) Cancer chemotherapy and biotherapy: principles and practice, 5th Edition edn. Wolters Kluwer\/Lippincott Williams & Wilkins, Philadelphia","edition":"5th Edition edn"},{"issue":"5","key":"3562_CR84","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1046\/j.1365-2141.2003.04702.x","volume":"123","author":"G Juliusson","year":"2003","unstructured":"Juliusson G, H\u00f6glund M, Karlsson K, L\u00f6fgren C, M\u00f6llg\u00e5rd L, Paul C, Tidefelt U, Bj\u00f6rkholm M, Sweden LGM (2003) Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 123(5):810\u2013818","journal-title":"Br J Haematol"},{"issue":"4","key":"3562_CR85","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.1993.11.4.671","volume":"11","author":"A Saven","year":"1993","unstructured":"Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD (1993) 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 11(4):671\u2013678. https:\/\/doi.org\/10.1200\/JCO.1993.11.4.671","journal-title":"J Clin Oncol"},{"issue":"4","key":"3562_CR86","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/0003-4819-119-4-199308150-00005","volume":"119","author":"A Saven","year":"1993","unstructured":"Saven A, Piro LD (1993) Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2\u2032-deoxycoformycin. Ann Intern Med 119(4):278\u2013283","journal-title":"Ann Intern Med"},{"issue":"3","key":"3562_CR87","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","volume":"10","author":"VM Santana","year":"1992","unstructured":"Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10(3):364\u2013370. https:\/\/doi.org\/10.1200\/JCO.1992.10.3.364","journal-title":"J Clin Oncol"},{"issue":"10","key":"3562_CR88","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood.V84.10.3429.3429","volume":"84","author":"L Vahdat","year":"1994","unstructured":"Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP (1994) Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84(10):3429\u20133434","journal-title":"Blood"},{"issue":"2","key":"3562_CR89","first-page":"239","volume":"33","author":"J Holowiecki","year":"2002","unstructured":"Holowiecki J, Robak T, Kyrcz-Krzemie\u0144 S, Grosicki S, Wrzesie\u0144-Kus A, Hellmann A, Skotnicki A, J\u0119drzejczak W, Konopka L, Zdziarska B (2002) Daunorubicin, cytarabine and 2-CdA (DAC-7) for remission induction in \u201cde novo\u201d adult acute myeloid leukaemia patients. Evaluation of safety, tolerance and antileukemic activity. Acta Haematol Pol 33(2):239\u2013247","journal-title":"Acta Haematol Pol"},{"issue":"5","key":"3562_CR90","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.leu.2403336","volume":"18","author":"J Holowiecki","year":"2004","unstructured":"Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K, (PALG) PALG (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18(5):989\u2013997. https:\/\/doi.org\/10.1038\/sj.leu.2403336","journal-title":"Leukemia"},{"issue":"20","key":"3562_CR91","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O (2012) Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 30(20):2441\u20132448. https:\/\/doi.org\/10.1200\/JCO.2011.37.1286","journal-title":"J Clin Oncol"},{"issue":"7","key":"3562_CR92","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrclinonc.2012.98","volume":"9","author":"FR Appelbaum","year":"2012","unstructured":"Appelbaum FR (2012) Haematological cancer: the rule of three in AML induction\u2014is cladribine the answer? Nat Rev Clin Oncol 9(7):376\u2013377. https:\/\/doi.org\/10.1038\/nrclinonc.2012.98","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"3562_CR93","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117(8):2358\u20132365. https:\/\/doi.org\/10.1182\/blood-2010-03-273243","journal-title":"Blood"},{"issue":"3","key":"3562_CR94","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2015-08-662130","volume":"127","author":"M Libura","year":"2016","unstructured":"Libura M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, Florek I, Matiakowska K, Jazwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, Jakobczyk M, Karabin K, Paluszewska M, Calbecka M, Gajkowska-Kulik J, Gadomska G, Kielbinski M, Ejduk A, Kata D, Grosicki S, Wierzbowska A, Kyrcz-Krzemien S, Warzocha K, Kuliczkowski K, Skotnicki A, Holowiecki J, Jedrzejczak WW, Haus O (2016) Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood 127(3):360\u2013362. https:\/\/doi.org\/10.1182\/blood-2015-08-662130","journal-title":"Blood"},{"key":"3562_CR95","first-page":"3898","volume":"130","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian HM, Ravandi F, Jabbour EJ, Daver N, Pemmaraju N, DiNardo CD, Verstovsek S, Alvarado Y, Borthakur G, Jain N, Konopleva M, Benton CB, Slack R, Patel KP, Garcia-Manero G, Cortes JE, Kadia T (2017) Outcomes by treatment setting and genomic profile in patients with AML on cladribine, idarubicin, and cytarabine. Blood 130:3898","journal-title":"Blood"},{"key":"3562_CR96","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V120.21.4337.4337","volume":"120","author":"S Grosicki","year":"2012","unstructured":"Grosicki S, Kriegler M, Bodzenta E, Twardosz M, Szypula I, Fejklowicz M, Haus O, Kurzawa T, Barchnicka A (2012) Comparable toxicity and outcome of acute myeloid leukemia (AML) fit patients therapy independently if daunorubicin or idarubicin were added to cytarabine\/cladribine induction regimens\u2014the single centre study. Blood 120:4337","journal-title":"Blood"},{"key":"3562_CR97","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood.V128.22.3988.3988","volume":"128","author":"MW Schoen","year":"2016","unstructured":"Schoen MW, Woelich SK, Braun JT, Fesler MJ, Petruska PJ, Freter CE, Lionberger JM (2016) Acute myeloid leukemia induction with cladribine: effects of age and leukemia risk. Blood 128:3988","journal-title":"Blood"},{"issue":"11","key":"3562_CR98","first-page":"6287","volume":"35","author":"E Wiedower","year":"2015","unstructured":"Wiedower E, Jamy O, Martin MG (2015) Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine. Anticancer Res 35(11):6287\u20136290","journal-title":"Anticancer Res"},{"issue":"5\u20136","key":"3562_CR99","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000440943","volume":"60","author":"Y Shen","year":"2014","unstructured":"Shen Y, Chen J, Liu Y, Wu D (2014) Addition of cladribine to idarubicin and cytarabine during induction increases the overall efficacy rate in adult patients with acute myeloid leukemia: a matched-pair retrospective comparison. Chemotherapy 60(5\u20136):368\u2013374. https:\/\/doi.org\/10.1159\/000440943","journal-title":"Chemotherapy"},{"issue":"5","key":"3562_CR100","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1060028017749214","volume":"52","author":"ND Seligson","year":"2018","unstructured":"Seligson ND, Hobbs ALV, Leonard JM, Mills EL, Evans AG, Goorha S (2018) Evaluating the impact of the addition of cladribine to standard acute myeloid leukemia induction therapy. Ann Pharmacother 52(5):439\u2013445. https:\/\/doi.org\/10.1177\/1060028017749214","journal-title":"Ann Pharmacother"},{"issue":"1\u20132","key":"3562_CR101","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10428190009053545","volume":"39","author":"T Robak","year":"2000","unstructured":"Robak T, Wrzesie\u0144-Ku\u015b A, Lech-Mara\u0144da E, Kowal M, Dmoszy\u0144ska A (2000) Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 39(1\u20132):121\u2013129. https:\/\/doi.org\/10.3109\/10428190009053545","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3562_CR102","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"A Wierzbowska","year":"2008","unstructured":"Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Ho\u0142owiecki J, Kyrcz-Krzemie\u0144 S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kie\u0142bi\u0144ski M, Zawilska K, K\u0142oczko J, Wrzesie\u0144-Ku\u015b A, Group PAL (2008) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 80(2):115\u2013126. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00988.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"3562_CR103","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3816\/CLM.2009.n.058","volume":"9","author":"MG Martin","year":"2009","unstructured":"Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN (2009) Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma 9(4):298\u2013301. https:\/\/doi.org\/10.3816\/CLM.2009.n.058","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"3562_CR104","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.leukres.2013.12.010","volume":"38","author":"MV Jaglal","year":"2014","unstructured":"Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS (2014) Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res 38(4):443\u2013446. https:\/\/doi.org\/10.1016\/j.leukres.2013.12.010","journal-title":"Leuk Res"},{"key":"3562_CR105","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","volume":"32","author":"AB Halpern","year":"2018","unstructured":"Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB (2018) Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia 32:2352\u20132362. https:\/\/doi.org\/10.1038\/s41375-018-0135-8","journal-title":"Leukemia"},{"issue":"24","key":"3562_CR106","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854\u20134860. https:\/\/doi.org\/10.1182\/blood-2013-01-466706","journal-title":"Blood"},{"issue":"4","key":"3562_CR107","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ajh.24654","volume":"92","author":"A Pluta","year":"2017","unstructured":"Pluta A, Robak T, Wrzesien-Kus A, Katarzyna Budziszewska B, Sulek K, Wawrzyniak E, Czemerska M, Zwolinska M, Golos A, Holowiecka-Goral A, Kyrcz-Krzemien S, Piszcz J, Kloczko J, Mordak-Domagala M, Lange A, Razny M, Madry K, Wiktor-Jedrzejczak W, Grosicki S, Butrym A, Kuliczkowski K, Warzocha K, Holowiecki J, Giebel S, Szydlo R, Wierzbowska A (2017) Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol 92(4):359\u2013366. https:\/\/doi.org\/10.1002\/ajh.24654","journal-title":"Am J Hematol"},{"issue":"9","key":"3562_CR108","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","volume":"5","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O\u2019Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H (2018) Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411\u2013e421. https:\/\/doi.org\/10.1016\/S2352-3026(18)30132-7","journal-title":"Lancet Haematol"},{"key":"3562_CR109","unstructured":"Kadia T, Cortes J, Borthakur G, Jabbour E, Daver N, Pemmaraju N, Verstovsek S, Burger J, Ferrajoli A, Wierda W, Konopleva M, DiNardo C, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Kantarjian H (2016) Phase II study of cladribine and low-dose araC alternating with decitabine in older patients with AML. EHA Learning Center:133175"},{"key":"3562_CR110","unstructured":"Cladribine plus low dose cytarabine (LDAC) alternating with decitabine in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). ClinicalTrials.gov Identifier: NCT01515527 National Library of Medicine, USA. https:\/\/clinicaltrials.gov ."},{"issue":"6","key":"3562_CR111","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918\u20131926","journal-title":"Blood"},{"issue":"Suppl 2","key":"3562_CR112","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/10428194.2011.565097","volume":"52","author":"T Tadmor","year":"2011","unstructured":"Tadmor T (2011) Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):38\u201342. https:\/\/doi.org\/10.3109\/10428194.2011.565097","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"3562_CR113","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594\u20131604. https:\/\/doi.org\/10.1177\/1352458517727603","journal-title":"Mult Scler"},{"issue":"2","key":"3562_CR114","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/j.ijid.2009.02.021","volume":"14","author":"E Lech-Maranda","year":"2010","unstructured":"Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T (2010) Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis 14(2):e132\u2013e140. https:\/\/doi.org\/10.1016\/j.ijid.2009.02.021","journal-title":"Int J Infect Dis"},{"issue":"2","key":"3562_CR115","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2141.2011.08931.x","volume":"156","author":"G Jones","year":"2012","unstructured":"Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D, British Committee for Standards in Haematology (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156(2):186\u2013195. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08931.x","journal-title":"Br J Haematol"},{"issue":"9","key":"3562_CR116","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C, 5th European Conference on Infections in Leukaemia (ECIL-5) ajvotEGfBaMTE, the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN) (2016) ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71(9):2397\u20132404. https:\/\/doi.org\/10.1093\/jac\/dkw157","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3562_CR117","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2141.2010.08444.x","volume":"152","author":"J Treleaven","year":"2011","unstructured":"Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webb D (2011) Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology Blood Transfusion Task Force. Br J Haematol 152(1):35\u201351. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08444.x","journal-title":"Br J Haematol"},{"issue":"6","key":"3562_CR118","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3109\/10428194.2011.635864","volume":"53","author":"C Ganzel","year":"2012","unstructured":"Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N (2012) High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma 53(6):1169\u20131173. https:\/\/doi.org\/10.3109\/10428194.2011.635864","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"3562_CR119","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1200\/JCO.1994.12.10.2216","volume":"12","author":"BD Cheson","year":"1994","unstructured":"Cheson BD, Vena DA, Foss FM, Sorensen JM (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12(10):2216\u20132228. https:\/\/doi.org\/10.1200\/JCO.1994.12.10.2216","journal-title":"J Clin Oncol"},{"issue":"6","key":"3562_CR120","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K (2015) No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2(6):e158. https:\/\/doi.org\/10.1212\/NXI.0000000000000158","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3562_CR121","unstructured":"Decitabine, filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride in treating patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. ClinicalTrials.gov Identifier: NCT02921061. https:\/\/clinicaltrials.gov ."},{"key":"3562_CR122","unstructured":"Filgrastim, cladribine, cytarabine, and mitoxantrone with sorafenib tosylate in treating patients with newly-diagnosed, acute myeloid leukemia or high-risk myelodysplastic syndrome. ClinicalTrials.gov Identifier: NCT02728050. https:\/\/clinicaltrials.gov ."},{"key":"3562_CR123","unstructured":"Cladribine plus idarubicin plus cytarabine (ARAC) in patients with acute myeloid leukemia (AML), high risk myelodysplastic syndrome (HR MDS) or myeloid blast phase of chronic myeloid leukemia (CML). ClinicalTrials.gov Identifier: NCT02115295. https:\/\/clinicaltrials.gov ."},{"key":"3562_CR124","unstructured":"4-Arm phase II study of SGI-110 in elderly acute myeloid leukemia (AML). ClinicalTrials.gov Identifier: NCT02096055 https:\/\/clinicaltrials.gov ."},{"key":"3562_CR125","unstructured":"Higher or lower dose cladribine, cytarabine, and mitoxantrone in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm. ClinicalTrials.gov Identifier: NCT03012672 https:\/\/clinicaltrials.gov ."},{"key":"3562_CR126","unstructured":"Idarubicin plus cytarabine (IA) vs IA plus cladribine (IAC) as induction regimen to treat initially diagnosed acute myeloid leukemia (AML). ClinicalTrials.gov Identifier: NCT02323022 https:\/\/clinicaltrials.gov ."},{"key":"3562_CR127","unstructured":"A PALG prospective multicenter clinical trial to compare the efficacy of two standard induction therapies (DA-90 vs DAC) and two standard salvage regimens (FLAG-IDA vs CLAG-M) in AML patients \u2264 60 years old (PALG-AML1\/2016) https:\/\/clinicaltrials.gov\/"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3562-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:14:21Z","timestamp":1775279661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3562-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3562-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}